Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Accumulated Expenses (2020 - 2026)

Maxcyte has reported Accumulated Expenses over the past 6 years, most recently at $7.8 million for Q4 2025.

  • Quarterly Accumulated Expenses fell 5.9% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, down 5.9% year-over-year, with the annual reading at $7.8 million for FY2025, 5.9% down from the prior year.
  • Accumulated Expenses was $7.8 million for Q4 2025 at Maxcyte, down from $8.3 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $11.3 million in Q4 2023 and troughed at $3.9 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $7.1 million (2024), against an average of $7.2 million.
  • Year-over-year, Accumulated Expenses skyrocketed 78.59% in 2023 and then decreased 26.33% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $6.5 million in 2021, then grew by 26.7% to $8.3 million in 2022, then skyrocketed by 36.35% to $11.3 million in 2023, then decreased by 26.33% to $8.3 million in 2024, then fell by 5.9% to $7.8 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Accumulated Expenses are $7.8 million (Q4 2025), $8.3 million (Q3 2025), and $6.4 million (Q2 2025).